In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates

Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02423-17. doi: 10.1128/AAC.02423-17. Print 2018 May.

Abstract

The objective of this study was to assess the in vitro activity of the novel triazole antifungal drug, efinaconazole, and five comparators (luliconazole, lanoconazole, terbinafine, itraconazole, and fluconazole) against a large collection of Trichophyton interdigitale and Trichophyton rubrum clinical isolates. The geometric mean MICs were the lowest for luliconazole (0.0005 μg/ml), followed by lanoconazole (0.002 μg/ml), efinaconazole (0.007 μg/ml), terbinafine (0.011 μg/ml), itraconazole (0.095 μg/ml), and fluconazole (12.77 μg/ml). It appears that efinaconazole, lanoconazole, and luliconazole are promising candidates for the treatment of dermatophytosis due to T. interdigitale and T. rubrum.

Keywords: dermatophytes; efinaconazole; in vitro susceptibility testing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Arthrodermataceae / drug effects*
  • Fluconazole / pharmacology
  • Imidazoles / pharmacology
  • Itraconazole / pharmacology
  • Microbial Sensitivity Tests
  • Terbinafine / pharmacology
  • Triazoles / pharmacology*

Substances

  • Antifungal Agents
  • Imidazoles
  • Triazoles
  • Itraconazole
  • latoconazole
  • Fluconazole
  • Terbinafine
  • efinaconazole